Brookline Capital Markets Forecasts ERNA Q2 Earnings

Ernexa Therapeutics Inc. (NASDAQ:ERNA) – Investment analysts at Brookline Capital Markets dropped their Q2 2026 earnings per share estimates for Ernexa Therapeutics in a research note issued to investors on Wednesday, May 27th. Brookline Capital Markets analyst K. Raja now anticipates that the company will earn ($3.30) per share for the quarter, down from their previous forecast of ($2.11). Brookline Capital Markets has a “Buy” rating and a $30.00 price objective on the stock. The consensus estimate for Ernexa Therapeutics’ current full-year earnings is ($18.02) per share. Brookline Capital Markets also issued estimates for Ernexa Therapeutics’ Q3 2026 earnings at ($3.84) EPS, Q4 2026 earnings at ($4.76) EPS, FY2026 earnings at ($18.02) EPS, FY2027 earnings at ($1.86) EPS, FY2028 earnings at ($1.27) EPS, FY2029 earnings at ($1.44) EPS and FY2030 earnings at ($1.65) EPS.

Ernexa Therapeutics (NASDAQ:ERNA) last released its quarterly earnings data on Monday, May 11th. The company reported ($6.95) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.95) by ($5.00).

Several other equities research analysts have also recently commented on ERNA. Wall Street Zen cut Ernexa Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Ernexa Therapeutics in a research report on Tuesday, April 21st. Finally, Zacks Research raised Ernexa Therapeutics to a “hold” rating in a research note on Monday, May 11th. One equities research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Ernexa Therapeutics presently has an average rating of “Hold” and an average price target of $30.00.

Ernexa Therapeutics Stock Performance

ERNA opened at $10.57 on Monday. Ernexa Therapeutics has a 12-month low of $3.18 and a 12-month high of $91.54. The stock has a fifty day simple moving average of $7.09 and a two-hundred day simple moving average of $18.16. The company has a market cap of $12.37 million, a price-to-earnings ratio of -0.40 and a beta of 2.47.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Ernexa Therapeutics stock. Susquehanna International Group LLP bought a new position in shares of Ernexa Therapeutics Inc. (NASDAQ:ERNA) during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 30,854 shares of the company’s stock, valued at approximately $34,000. Susquehanna International Group LLP owned 0.39% of Ernexa Therapeutics as of its most recent SEC filing. Hedge funds and other institutional investors own 70.55% of the company’s stock.

About Ernexa Therapeutics

Eterna Therapeutics Inc, a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited. Eterna Therapeutics Inc was founded in 2018 and is based in Cambridge, Massachusetts.